# Mirum Pharmaceuticals

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/mirum-pharmaceuticals

- Industry: Biotechnology
- Headquarters: Foster City, US
- Website: www.mirumpharma.com
- Total disclosed funding: $120M
- Latest round: Series A (Nov 7, 2018)
- Investors on record: 7

## About

Mirum Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing transformative therapies for patients with rare diseases. Their innovative medicines aim to significantly improve patients' lives and healthcare outcomes.Founded in 2018 and headquartered in Foster City, US, Mirum Pharmaceuticals, Inc. specializes in creating treatments for rare diseases. The company has successfully raised a total of USD 80.00 mn, with its most recent funding round occurring in 2019 with a Private Placement/Follow-On worth USD 80.00 mn. Chris Peetz serves as the CEO.Mirum Pharmaceuticals focuses on developing transformative medicines aimed at addressing the unmet needs of patients with rare diseases. Their core offerings include innovative therapies that leverage scientific discoveries to significantly alter the treatment landscape for these conditions. The company emphasizes a patient-centric approach, aiming to enhance the quality of life for those affected and their families. Mirum's products are designed to provide medical solutions and improve daily experiences for patients, serving a global client base with a focus on North America, Europe, and select regions in Asia.Mirum Pharmaceuticals generated revenue of USD 336.89 mn in 2024, with an EBITDA of USD -62.32 mn. The company primarily earns revenue through the commercialization of its pharmaceutical products, which are distributed to healthcare providers, hospitals, and specialty pharmacies. Their business model includes both direct-to-consumer and B2B transactions, enabling healthcare professionals to prescribe their therapies as part of treatment plans for patients with rare diseases.Mirum Pharmaceuticals has plans to expand its product offerings and market presence. The company aims to launch upcoming therapies designed for rare diseases, although specific release dates are not disclosed. Additionally, the firm is targeting expansion into new geographical regions, with a focus on increasing its market presence in Europe and select areas in Asia by 2025. Recent funding will be utilized to further support these initiatives, including their IPO in July 2019 which raised USD 75.00 mn and a public offering in December 2020 that brought in USD 48.00 mn.

## Funding rounds

- Series A, Nov 7, 2018, $120M — Frazier Healthcare Partners, New Enterprise Associates, Pappas Capital, RiverVest Ventures Partners, Novo Holdings, Deerfield Management, Rock Springs Capital

## Investors

- Frazier Healthcare Partners (https://capitalatlas.ai/funds/frazier-healthcare-partners) — Series A
- New Enterprise Associates (https://capitalatlas.ai/funds/new-enterprise-associates) — Series A
- Pappas Capital (https://capitalatlas.ai/funds/pappas-capital) — Series A
- RiverVest Ventures Partners (https://capitalatlas.ai/funds/rivervest-ventures-partners) — Series A
- Novo Holdings — Series A
- Deerfield Management (https://capitalatlas.ai/funds/deerfield-management) — Series A
- Rock Springs Capital — Series A